Karen Garner, a 73-year-old woman living with dementia, was walking home from the store when wildflowers growing on the side of the road caught…
Today, the experimental Eli Lilly drug donanemab received the FDA’s “breakthrough therapy designation” based on its potential to treat Alzheimer’s disease. The FDA granted…
Image: Aduhelm, Biogen/AP. “The approach I’ve been taking is that each decision about whether or not to offer this as a treatment has to…
Whether it’s forgetting a name or where we placed our keys and cell phone, memory lapses can be especially worrying for aging adults with…
When Kathy Kenyon’s parents — both with early-stage dementia — moved to the Washington, D.C. area, it took months for medical records to be…
UPDATE: 3 March 2024, 8:26 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
Instead of developing a new drug from the ground up — a time-consuming and costly process — experts say that repurposing medications could accelerate…
For retired neurologist Daniel Gibbs, an Alzheimer’s diagnosis gave him not only a sense of relief, but a new lifestyle: one of healthier living,…
Retired neurologist Daniel Gibbs speaks about his own Alzheimer’s diagnosis, his unusual and severe case of side effects in aducanumab (Aduhelm) clinical trials, and…
In light of last week’s long-awaited FDA decision on experimental Alzheimer’s treatment aducanumab, a panel of clinical trials experts looks at why Alzheimer’s drug…
Imran Sherwani, olympic gold medalist, was diagnosed with early-onset Alzheimer’s in 2019, and revealed his diagnosis this month. Sherwani revels in the life he’s…
The FDA’s approval of Biogen’s new anti-amyloid drug Aduhelm was a landmark moment for Alzheimer’s — and it comes with no small amount of…
UPDATE: 3 March 2024, 8:33 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
Looking for answers about Alzheimer’s treatment Aduhelm (generic name aducanumab)? Here’s a primer on what it is, what it does, and more, according to…
As an aducanumab trial participant, Phil Gutis, a reporter with early-stage Alzheimer’s, was part of Aduhelm’s journey to FDA approval. Doctors can soon start…